BACKGROUND: The assessment of acute heart failure (AHF) in patients with acute coronary syndrome (ACS) is challenging. This study tested whether measuring plasma adrenomedullin in patients admitted for ACS provides valuable information regarding the presence of AHF at admission or its occurrence during hospitalization. METHODS AND RESULTS: The study population consisted of 927 prospectively enrolled patients with ACS. Blood samples for the measurement of plasma bio-adrenomedullin (bio-ADM) were collected at admission. Patients with alveolar pulmonary edema and interstitial pulmonary edema on chest radiography at admission had stepwise higher plasma concentrations of bio-ADM compared to patients with no or mild pulmonary congestion: 54.3 ± 10.6 vs. 27.6 ± 2.1 vs. 22.5 ± 0.7 ng/L, overall P < 0.001. Patients with ACS complicated by AHF during the index hospitalization displayed higher plasma bio-ADM concentrations at admission compared to patients without AHF (33.8 ± 2.7 vs. 21.8 ± 0.7, P < 0.001): the higher the severity of AHF, the higher plasma bio-ADM concentrations at admission. Patients with cardiogenic shock displayed the highest values. Accordingly, bio-ADM concentrations at admission were associated with a higher risk of occurrence of AHF during index hospitalization (odds ratio 1.018, 95% confidence interval 1.011-1.026, P < 0.001). CONCLUSIONS: Plasma adrenomedullin is a marker associated with AHF severity in patients with ACS.

Department of Cardiology University Hospital Zurich Zurich Switzerland

Department of Internal Medicine and Cardiology University Hospital Brno Brno Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

INSERM UMR S 942 Université Paris Diderot PRES Sorbonne Paris Cité Department of Anesthesiology and Critical Care Medicine AP HP Saint Louis and Lariboisière University Hospitals Paris France

See more in PubMed

Arrigo M., Gayat E., Parenica J., Ishihara S., Zhang J., Choi D.-J., Park J.J., AlHabib K.F., Sato N., Miró Ò., Maggioni A.P., Zhang Y., Spinar J., Cohen-Solal A., Iwashyna T.J., Mebazaa A. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur. J. Heart Fail. 2017;19:201–208. PubMed

Fonarow G.C., Abraham W.T., Albert N.M., Stough W.G., Gheorghiade M., Greenberg B.H., O'Connor C.M., Pieper K., Sun J.L., Yancy C.W., Young J.B., OPTIMIZE-HF Investigators and Hospitals Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch. Intern. Med. 2008;168:847–854. PubMed

Bahit M.C., Lopes R.D., Clare R.M., Newby L.K., Pieper K.S., Van de Werf F., Armstrong P.W., Mahaffey K.W., Harrington R.A., Diaz R., Ohman E.M., White H.D., James S., Granger C.B. Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC Heart Fail. 2013;1:223–229. PubMed

Sabatine M.S., Morrow D.A., de Lemos J.A., Omland T., Desai M.Y., Tanasijevic M., Hall C., McCabe C.H., Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J. Am. Coll. Cardiol. 2004;44:1988–1995. PubMed

Kubena P., Arrigo M., Parenica J., Gayat E., Sadoune M., Ganovska E., Pavlusova M., Littnerova S., Spinar J., Mebazaa A., GREAT Network Plasma levels of soluble CD146 reflect the severity of pulmonary congestion better than brain natriuretic peptide in acute coronary syndrome. Ann. Lab. Med. 2016;36:300–305. PubMed PMC

Authors/Task Force Members, Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D, ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569–2619. PubMed

Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054. PubMed

Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit. Care; 2014;18:R34. PubMed PMC

Killip T., Kimball J.T. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am. J. Cardiol. 1967;20:457–464. PubMed

Kremer D., ter JM Maaten, Voors A.A. Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure. Eur. J. Heart Fail. 2018;20:1363–1365. PubMed

Proenkephalin improves cardio-renal risk prediction in acute coronary syndromes: the KID-ACS score